VanEck Associates’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$168M Sell
1,204,597
-55,049
-4% -$7.71M 0.13% 147
2025
Q4
$155M Buy
1,259,646
+624
+0% +$75.8K 0.13% 143
2025
Q3
$140M Sell
1,259,022
-4,961
-0.4% -$564K 0.13% 141
2025
Q2
$140M Sell
1,263,983
-2,131,792
-63% -$227M 0.16% 122
2025
Q1
$380M Sell
3,395,775
-2,727,494
-45% -$281M 0.49% 49
2024
Q4
$566M Sell
6,123,269
-219,562
-3% -$19.8M 0.72% 30
2024
Q3
$553M Buy
6,342,831
+22,847
+0.4% +$1.74M 0.69% 32
2024
Q2
$434M Buy
6,319,984
+747,831
+13% +$49.9M 0.62% 34
2024
Q1
$408M Buy
5,572,153
+579,738
+12% +$44.6M 0.62% 45
2023
Q4
$404M Buy
4,992,415
+457,576
+10% +$35.6M 0.74% 35
2023
Q3
$340M Buy
4,534,839
+702,342
+18% +$54M 0.75% 29
2023
Q2
$295M Buy
3,832,497
+1,832,292
+92% +$146M 0.65% 34
2023
Q1
$166M Buy
2,000,205
+18,287
+0.9% +$1.51M 0.38% 77
2022
Q4
$170M Sell
1,981,918
-1,681,089
-46% -$133M 0.44% 62
2022
Q3
$226M Sell
3,663,007
-206,643
-5% -$13M 0.67% 35
2022
Q2
$239M Buy
3,869,650
+311,736
+9% +$19.3M 0.63% 35
2022
Q1
$212M Buy
3,557,914
+236,611
+7% +$15.1M 0.44% 53
2021
Q4
$241M Buy
3,321,303
+149,594
+5% +$10.3M 0.56% 43
2021
Q3
$222M Buy
3,171,709
+208,266
+7% +$14.6M 0.56% 40
2021
Q2
$204M Buy
2,963,443
+403,756
+16% +$27M 0.48% 44
2021
Q1
$165M Buy
2,559,687
+342,846
+15% +$22.1M 0.45% 48
2020
Q4
$129M Buy
2,216,841
+332,288
+18% +$20.1M 0.38% 55
2020
Q3
$119M Buy
1,884,553
+125,630
+7% +$8.71M 0.38% 50
2020
Q2
$135M Buy
1,758,923
+182,106
+12% +$14M 0.47% 33
2020
Q1
$118M Sell
1,576,817
-138,704
-8% -$9.58M 0.6% 24
2019
Q4
$111M Buy
1,715,521
+304,836
+22% +$19.9M 0.43% 40
2019
Q3
$89.4M Buy
1,410,685
+9,855
+0.7% +$644K 0.42% 38
2019
Q2
$94.6M Buy
1,400,830
+103,768
+8% +$6.83M 0.46% 39
2019
Q1
$84.3M Buy
1,297,062
+218,854
+20% +$14.5M 0.41% 46
2018
Q4
$67.4M Buy
1,078,208
+50,893
+5% +$3.56M 0.34% 53
2018
Q3
$79.3M Buy
1,027,315
+217,516
+27% +$16.4M 0.39% 57
2018
Q2
$57.4M Sell
809,799
-29,167
-3% -$2.06M 0.27% 85
2018
Q1
$63.3M Sell
838,966
-241,163
-22% -$19.2M 0.31% 74
2017
Q4
$77.4M Buy
1,080,129
+14,399
+1% +$1.09M 0.38% 64
2017
Q3
$86.3M Sell
1,065,730
-358,011
-25% -$27.4M 0.44% 55
2017
Q2
$101M Buy
1,423,741
+12,134
+0.9% +$807K 0.55% 46
2017
Q1
$95.9M Buy
1,411,607
+201,992
+17% +$14.2M 0.42% 61
2016
Q4
$86.6M Buy
1,209,615
+97,402
+9% +$7.24M 0.43% 62
2016
Q3
$88M Buy
1,112,213
+47,722
+4% +$3.88M 0.41% 63
2016
Q2
$88.8M Sell
1,064,491
-77,280
-7% -$6.86M 0.46% 53
2016
Q1
$105M Buy
1,141,771
+234,244
+26% +$21.1M 0.71% 41
2015
Q4
$91.8M Sell
907,527
-159,651
-15% -$16.6M 0.73% 37
2015
Q3
$105M Sell
1,067,178
-16,122
-1% -$1.79M 0.81% 33
2015
Q2
$127M Sell
1,083,300
-457,634
-30% -$50M 0.75% 37
2015
Q1
$151M Buy
1,540,934
+654,743
+74% +$66.5M 0.87% 32
2014
Q4
$83.5M Buy
886,191
+91,746
+12% +$9.49M 0.52% 54
2014
Q3
$84.6M Sell
794,445
-88,899
-10% -$8.7M 0.45% 54
2014
Q2
$73.2M Sell
883,344
-94,115
-10% -$7.33M 0.34% 69
2014
Q1
$69.3M Buy
977,459
+33,151
+4% +$2.6M 0.34% 65
2013
Q4
$70.9M Buy
944,308
+61,925
+7% +$4.31M 0.36% 66
2013
Q3
$55.5M Buy
882,383
+267,114
+43% +$16M 0.28% 74
2013
Q2
$31.5M Buy
+615,269
New +$32.1M 0.17% 91

Other funds holding GILD

VanEck Associates's GILD Position: Q1 2026 in Review

VanEck Associates reduced its Gilead Sciences (GILD) stake by 4.4% in Q1 2026, selling an estimated $7.71M and leaving 1,204,597 shares worth $168M. The position accounts for 0.13% of the portfolio, ranked #147.

VanEck Associates first reported a position in GILD in Q2 2013 and has held it in 52 quarters since. The position peaked at $566M in Q4 2024. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • VanEck Associates held 1,204,597 shares of Gilead Sciences worth $168M as of Q1 2026.
  • VanEck Associates sold 55,049 Gilead Sciences shares in Q1 2026, an estimated $7.71M.
  • Gilead Sciences made up 0.13% of VanEck Associates's portfolio in Q1 2026, its #147 holding.
  • VanEck Associates first reported a position in Gilead Sciences in Q2 2013 and has held it in 52 quarters since.
  • VanEck Associates's Gilead Sciences position peaked at $566M in Q4 2024.
  • 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on VanEck Associates's 13F filing for Q1 2026, filed 15 May 2026.